Ironwood Pharmaceuticals, Inc.
IRWD
$3.25
-$0.12-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -60.91% | 43.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -60.91% | 43.20% | |||
| Cost of Revenue | -2.69% | -3.87% | |||
| Gross Profit | -74.05% | 60.98% | |||
| SG&A Expenses | -11.94% | 30.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.26% | 10.48% | |||
| Operating Income | -91.56% | 72.36% | |||
| Income Before Tax | -99.33% | 79.84% | |||
| Income Tax Expenses | -90.23% | 96.44% | |||
| Earnings from Continuing Operations | -105.68% | 69.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -105.68% | 69.84% | |||
| EBIT | -91.56% | 72.36% | |||
| EBITDA | -91.03% | 71.63% | |||
| EPS Basic | -105.67% | 69.36% | |||
| Normalized Basic EPS | -99.70% | 86.36% | |||
| EPS Diluted | -110.51% | 66.96% | |||
| Normalized Diluted EPS | -99.68% | 85.92% | |||
| Average Basic Shares Outstanding | 0.14% | 0.30% | |||
| Average Diluted Shares Outstanding | -8.62% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||